Gene Editing Shop Recombinetics Surpasses $2M Fundraising Goal | GenomeWeb

NEW YORK (GenomeWeb News) – Gene editing firm Recombinetics today said that it surpassed its $2 million fundraising goal this month.

The St. Paul, Minn.-based firm did not disclose its investors.

Founded in 2008, Recombinetics is using a gene editing technology called TALENs to produce its first biomedical product and to develop the first agricultural products, it said on its website.

TALENs are sequence-specific DNA scissors that can be custom engineered to target and modify any gene of interest in any species.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.